ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025
A comprehensive clinico-pathological review of a series of pediatric, adolescents and young adults with high-grade osteosarcoma: from clinics to biomarker discovery.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Heat Shock Proteins as Cancer Biomarkers: From Mechanism to Clinical Application.Molecular diagnosis & therapy · 2026Review
- A Putative Hsa-miR-582-5p-CD81 Relationship Identified by Integrative Transcriptomic Analysis in Osteosarcoma.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundWe analyzed clinical and immunohistochemical characteristics of pediatric, adolescents and young adults with high-grade osteosarcoma (HGOS) to validate prognostic factors, identify targetable and prognostic biomarkers and define management of multiple relapses.
methodsRetrospective analysis of 67 patients with HGOS between 2001 and 2020 was studied. BTN3A2, HSP90 and GLYPICAN1 were further analyzed based on their high expression on in silico model.
resultsConventional osteosarcoma was the most frequent histology subtype (89.5%); 26.9% of patients had metastases at diagnosis. Proportion of limb-sparing surgery and R0 resection increased before and after 2011 (66.6% vs. 96.2%; 78.5% vs 87.5% respectively), while no treatment-related deaths occurred after 2011. 5-year OS and EFS were 61% and 56.6%, (5.4-year median follow-up (0.20-17.40). In multivariate analysis, metastatic disease was the sole independent prognostic factor. 5-year EFS and OS for patients with 1st, 2nd, and 3rd relapse were 8-12%, 0-5%, and 11.1-11.1% respectively. BTN3A2 was highly expressed at diagnosis, surgery, and relapse.
conclusionMetastatic disease remains the most important prognosis factor in HGOS. Improvements in surgical procedures and reduction in treatment-related mortality were observed. Survival after multiple relapses remains poor; we define figures to be used for benchmarking in clinical trials. BTN3A2 is a potential therapeutic target.
Indexed as
Identifiers
40198505What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.